Loading provider…
Loading provider…
Medical Oncology Physician in Los Angeles, CA
NPI: 1154611218HQ Phone
Get M.D. Bing's Phone Numberphone_androidMobile
Get M.D. Bing's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2017 - 2025
CT State Medical License
2014 - 2020
RI State Medical License
2017 - 2018
CA State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of Pennsylvania
BA • Biology
—
Yale-New Haven Medical Center
Residency • Internal Medicine
2011 - 2014
Fellowship • Hematology and Medical Oncology
2014 - 2017
Albert Einstein College of Medicine
einsteinmed.edu
Medical School
Until 2011
Authors: Wu, Kan, Chen, Xueqin, Chen, Xufeng, Zhang, Shirong, Xu, Yasi, Xia, Bing, Ma, Shenglin
Journal: J Int Med Res
Authors: Feng, Huichun, Wang, Hui, Xu, Lixia, Ren, Yao, Ni, Qianxi, Yang, Zhen, Ma, Shenglin, Deng, Qinghua, Chen, Xueqin, Xia, Bing, Kuang, Yu, Li, Xiadong
Journal: Front Oncol
Publication Date: 2022-11-10
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Osimertinib, BIOLOGICAL: Bevacizumab, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, PROCEDURE: Biopsy Procedure
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, DRUG: Cabozantinib S-malate
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: paclitaxel, DRUG: pembrolizumab, DRUG: nab-paclitaxel, DRUG: pemetrexed, DRUG: canakinumab, DRUG: canakinumab-matching placebo